MK-2206 2HCl 化学構造
分子量: 480.39

高品質保証

文献中の引用(166)

カスタマーフィードバック(19)

Quality Control & MSDS

製品説明

  • Compare Akt Inhibitors
    Akt製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 MK-2206 2HClは高度選択的に Akt1, Akt2 and Akt3を抑制して、 IC50がそれぞれ 8 nM, 12 nM と 65 nMになる。
ターゲット Akt1 Akt2 Akt3
IC50 8 nM 12 nM 65 nM [1]
In vitro試験 MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity Description
NCI-H292 NWTWXXh3S3m2b4TvfIlkKEG|c3H5 MlnKN{DPxE1? NGf1XJI4OiCq MXfEUXNQ M3flOGlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w
A431 MoDWT4lv[XOnIFHzd4F6 NHXq[Hk2KM7:TR?= NUXqR3UxPSCq M2P6ZmROW09? M4nWTHN2eHC{ZYPz[ZMhfGinIIPp[45idGmwZzDv[kBCc3RiYX7kJGVzcw>?
HepG2 MV;DfZRwfG:6aXOgRZN{[Xl? NInRcG0yOCEQvF2= NYq0XXlmOjRiaB?= MknpSG1UVw>? NV7DdZF4W2Wwc3n0bZpmeyC{ZYPpd5RidnRiY3XscJMhfG9idHjlJIN6fG:2b4jpZ{Bm\m[nY4Sgc4Yhe2:{YX\lcolj
Sk-Hep1 NFWySIJEgXSxdH;4bYMhSXO|YYm= M{T6clExKM7:TR?= NV\rVIdKOjRiaB?= M3mzZ2ROW09? NUXObWg6W2Wwc3n0bZpmeyC{ZYPpd5RidnRiY3XscJMhfG9idHjlJIN6fG:2b4jpZ{Bm\m[nY4Sgc4Yhe2:{YX\lcolj
OCUT1 cells harbored PIK3CA (H1047R+/+) MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyzJO69VQ>? MXu1JIQ> MX3EUXNQ MmjrTWM2OD1yLkG0JO69VQ>?
K1 cells harbored PIK3CA (E542K+/+) Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M174SlMh|ryP MmiwOUBl NH3V[ZpFVVOR Mm\rTWM2OD1yLkWyJO69VQ>?
FTC133 cells harbored PTEN (allele deletion and R130+) MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVryeVNmOyEQvF2= NWLsWoJ7PSCm NELaWo9FVVOR NYTafGFqUUN3ME2wMlE5KM7:TR?=
C643 cells harbored HRAS (G13R+/−) MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvWSnpEOyEQvF2= MYC1JIQ> MnTySG1UVw>? Mn7tTWM2OD1yLkK3JO69VQ>?
Hth7 cells harbored NRAS (Q61R+/−) MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfSR4U{KM7:TR?= MXS1JIQ> MmjBSG1UVw>? MmXmTWM2OD12LkWg{txO
TPC1 cells harbored RET/PTC1 rearrangement MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\pUVMh|ryP MXu1JIQ> M1;5emROW09? NYW3U3pWUUN3ME2wMlU6KM7:TR?=
Hth74 Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOzJO69VQ>? M2\mNVUh\A>? NEC0[nlFVVOR MXTJR|UxRTJwMUmg{txO
KAT18 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fXb|Mh|ryP NEe4eVA2KGR? NWHIXIZQTE2VTx?= NXvido9tUUN3ME20MlYzKM7:TR?=
SW1736 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7kNVAxKM7:TR?= NXXLO|RPPSCm NX\pVYx[TE2VTx?= NV3xTIlLUUN3ME20O{42PiEQvF2=
WRO M2HPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFz3PXgyODByIN88US=> NH7RSlk2KGR? NWPt[YxVTE2VTx?= M37RS2lEPTB-MUCwNEDPxE1?
TAD2 MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCxNFAxKM7:TR?= NUDxTmFrPSCm NYfiUpZOTE2VTx?= MkDrTWM2OD5zMECwJO69VQ>?
LN229 MYrBdI9xfG:|aYOgRZN{[Xl? NVjHNZg{OC53IN88US=> M3v2TFYxKGh? NXSzelRTTE2VTx?= NVfxdG5tSXWpbXXueJMh[XCxcITv[4VvcWNiZX\m[YN1eyCxZjDn[YZqfGmwaXK=
T98G NYLhWphWSXCxcITvd4l{KEG|c3H5 NXLoTnd7OC53IN88US=> NUnuTmY6PjBiaB?= NITnUnBFVVOR NYHIVIZFSXWpbXXueJMh[XCxcITv[4VvcWNiZX\m[YN1eyCxZjDn[YZqfGmwaXK=
HC11 MYrGeY5kfGmxbjDBd5NigQ>? NW[wWIJTOTBizszN M2CxWVI1KGh? NI\UUZdFVVOR NXXPdnJLUW6qaXLpeJMh|rJvY3Hz[YlvKGGwZDDBSHJRKHO7boTo[ZNqew>?
MOLT-4 MoTxR5l1d3SxeHnjJGF{e2G7 MYexNEDPxE1? M1rMRlQ5KGh? NInyWo1FVVOR NVnJZ|dJUUN3ME2xMlfjiIoQvF2=
CEM-R NI\0S|JEgXSxdH;4bYMhSXO|YYm= NUKwWZJjOTBizszN NYrwZY9MPDhiaB?= NIfaSJJFVVOR NGTo[W5KSzVyPUOuN-KBkc7:TR?=
CEM-S NHr3NWZEgXSxdH;4bYMhSXO|YYm= NHe0NYkyOCEQvF2= NHfhbHM1QCCq M3rFdWROW09? NFS4WXpKSzVyPUWuNgKBkc7:TR?=
MOLT-4 NHS2VWtHfW6ldHnvckBCe3OjeR?= MV[xNEDPxE1? MXKyOEBp Mnu4SG1UVw>? NIflXXpDdG:la4OgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOnIH;mJJRp\SClZXzsJIN6[2yn
MOLT-4 MnexSpVv[3Srb36gRZN{[Xl? M2j3TlTjiIoQvF2= M4DEblQhcA>? MXzEUXNQ NETzSmFKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDN2EwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ?
CEM-R MmjSSpVv[3Srb36gRZN{[Xl? NIfRUWk16oDLzszN NV:z[5lkPCCq NGPJWXdFVVOR NFvNVJVKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDOGEwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ?
CEM-S M1e5VmZ2dmO2aX;uJGF{e2G7 M1\WRVTjiIoQvF2= MVy0JIg> NFLTZ|NFVVOR NXjyeJcxUW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|VCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{
HepG2 cell MmDMT4lv[XOnIFHzd4F6 NUDlNXZGOjBizszN MWCyOEBp MnG3SG1UVw>? NVS5dZhsTG:5boLl[5Vt[XSnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?=
HepG2 cell MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[5TFMxKM7:TR?= MWOyOEBp MYfEUXNQ MmH0TY5pcWKrdIOgZ4VtdCCpcn;3eIg>
HepG2 cell NUnMXFB1SXCxcITvd4l{KEG|c3H5 MX2yNEDPxE1? NIrwN|czPCCq MUDEUXNQ MkT1TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?
GEO M4SzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fRUVUxOCCwTR?= NUTTXJhpPzJiaB?= NXLLeHlxTE2VTx?= MULJcohq[mm2czDj[YxtKGe{b4f0bC=>
CNE-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmGzNVAh|ryP NYS2RXV4QTZiaB?= NHHDPGJFVVOR M{LYbGlEPTB;Mj65OkDPxE1?
CNE-2 NVrY[Zo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fPbVExKM7:TR?= M{nyNVk3KGh? NXfibnhwTE2VTx?= NGjnOZBKSzVyPUSuOVMh|ryP
HONE-1 M2jPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxNEDPxE1? M1vTUVk3KGh? M3jOSWROW09? NV3SbGVQUUN3ME2zMlM4KM7:TR?=
SUNE-1 NIfscW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nPWVExKM7:TR?= MV:5OkBp Mn;BSG1UVw>? NFH5PZFKSzVyPUCuOVIh|ryP
CNE-2 NIDzUYJHfW6ldHnvckBCe3OjeR?= M{LxVlExKM7:TR?= MX[0PEBp M{e0fWROW09? MVrJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JGcy
HONE-1 MWPGeY5kfGmxbjDBd5NigQ>? MVmxNEDPxE1? MnHUOFghcA>? M1jtd2ROW09? M2XLZmlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhTzF?
NEC8 MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrVSVVlUUN3ME2wMlA6PjVzIN88US=>
P12-ICHIKAWA M{\SOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHDVIJKSzVyPUCuNVE3OiEQvF2=
MDA-MB-175-VII NF\HRolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33XbGlEPTB;MD6xN|c{QCEQvF2=
AsPC-1 M1K4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHKzTplKSzVyPUCuNlIyOjJizszN
T47D NVzBSHNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37BdmlEPTB;MD6yPFI2KM7:TR?=
HH NHzTW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M32wcmlEPTB;MD6zNFI5OyEQvF2=
MOLT-16 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHjTWM2OD1yLkOwN|Ih|ryP
ES5 NILJflFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX33OGc3UUN3ME2wMlM1PDV3IN88US=>
RS4-11 NFf3cXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nwUGlEPTB;MD6zOFYyKM7:TR?=
KARPAS-45 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS4T3lEUUN3ME2wMlM4OzJzIN88US=>
NCI-H720 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonpTWM2OD1yLkO3Olc6KM7:TR?=
H9 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj3O29KSzVyPUCuN|g5QDNizszN
EFM-19 M3n0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nsTWlEPTB;MD60OFAyKM7:TR?=
SBC-1 NXLydY9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC0cWRKSzVyPUCuOFQxOzVizszN
A4-Fuk NF7qS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrSNmhKSzVyPUCuOFY5PjhizszN
NCI-H1563 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\VO2lEPTB;MD60PFE5QSEQvF2=
HCC1419 NF7HcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPQTWM2OD1yLkS4PFkzKM7:TR?=
H-EMC-SS MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTjfFkxUUN3ME2wMlQ6QTN7IN88US=>
BHT-101 NYTPXXhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTBNYtmUUN3ME2wMlUzQTZzIN88US=>
IGROV-1 M3fGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\UZ3dJUUN3ME2wMlU2OjR7IN88US=>
HGC-27 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwNU[3PFMh|ryP
MDA-MB-361 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moe3TWM2OD1yLkW3O|YyKM7:TR?=
KE-37 M2LsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn2S4J4UUN3ME2wMlU5OjZizszN
HCC70 MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTvTWM2OD1yLkW5PFI4KM7:TR?=
LNCaP-Clone-FGC NEf4dIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jrcmlEPTB;MD62NVA1QCEQvF2=
HAL-01 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTxTWM2OD1yLk[yNVMh|ryP
HT M1[zOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4qxV2lEPTB;MD62N|I{QSEQvF2=
MDA-MB-415 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwNkO2NlYh|ryP
NOS-1 M3TRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwNkO3NlMh|ryP
DU-145 NIPqU|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jQfGlEPTB;MD62OFc1PSEQvF2=
OCUB-M NYDFdI1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LrZ2lEPTB;MD63NFk3PiEQvF2=
VA-ES-BJ MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HS[WlEPTB;MD63N|AzPSEQvF2=
J-RT3-T3-5 M2DmRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHKTWM2OD1yLke0OFA{KM7:TR?=
MOLT-4 Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG2e3ZKSzVyPUCuPFA2QDJizszN
NB7 Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[0N21ZUUN3ME2wMlgzPDFzIN88US=>
L-363 NFf6No1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwOEO0OFIh|ryP
NKM-1 MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rwSWlEPTB;MD64OlI2OyEQvF2=
HOP-92 NFXuOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG3XmhEUUN3ME2wMlg4OjJ|IN88US=>
OAW-42 NIfyc|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfPUXBKSzVyPUCuPFg4OiEQvF2=
HuO9 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2foOmlEPTB;MD65Nlc2OSEQvF2=
MFE-280 NYnmSYN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLITWM2OD1yLkm2OFY2KM7:TR?=
EM-2 MoDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3oNlZzUUN3ME2wMlk4QTN7IN88US=>
NCI-H520 MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTuTWM2OD1yLkm4OVkzKM7:TR?=
LB2241-RCC MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjafWdKSzVyPUCuPVk4OzRizszN
SK-NEP-1 NVTaRXBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPCNotKSzVyPUGuNVQ1QDVizszN
LXF-289 NH3JO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rH[WlEPTB;MT6xO|E2PiEQvF2=
EPLC-272H MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WxW2lEPTB;MT6xO|I2PiEQvF2=
COLO-684 MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f0TmlEPTB;MT6yN|czPSEQvF2=
ES1 MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3viS2lEPTB;MT6yOFA3PSEQvF2=
DOHH-2 NH34S4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S3cmlEPTB;MT6yPFIxOyEQvF2=
CTB-1 Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml34TWM2OD1zLkK4PVkh|ryP
G-401 NEDRXmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3idYx7UUN3ME2xMlI6Pzl3IN88US=>
LoVo Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\aXmVTUUN3ME2xMlMzPTN2IN88US=>
Ramos-2G6-4C10 M2W0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jMRmlEPTB;MT6zN|cxOSEQvF2=
MFM-223 NX3BW2Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLrUWt5UUN3ME2xMlM1PDZzIN88US=>
PA-1 NV\aV2hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XweWlEPTB;MT6zOVI3PSEQvF2=
697 NFW4OVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLveFRKSzVyPUGuN|c3OTZizszN
QIMR-WIL NVvtRWpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHqTWM2OD1zLkS5NVE3KM7:TR?=
HOS M17yc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFwNEm1OVgh|ryP
DMS-273 NGrKS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\Ec2lEPTB;MT61NVk2QSEQvF2=
ME-180 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFwNU[4PVEh|ryP
HCC2218 NIPMd|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHnTWM2OD1zLk[4NlI2KM7:TR?=
CAL-54 NH63NIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe2NXBKSzVyPUGuO|EzPDJizszN
OMC-1 NHXPbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFwN{S2O|ch|ryP
COR-L105 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP6PYxKSzVyPUGuO|k4OzdizszN
BV-173 NX7YPIF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFwOEGwO|Qh|ryP
RKO MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr6ZpdKSzVyPUGuPFcyODFizszN
SNU-387 M1PiOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:1TWM2OD1zLki4OFA3KM7:TR?=
SW1088 NGi4PINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\JeHJ5UUN3ME2xMlk1PjB4IN88US=>
Hs-578-T NVHuU5BCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYGw[ow4UUN3ME2yMlEyPDN|IN88US=>
OC-314 Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTJwMUWwPFYh|ryP
RMG-I MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJwMU[zPVgh|ryP
NCI-H1395 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HhbmlEPTB;Mj6xPFA6OSEQvF2=
GAMG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2qwT2lEPTB;Mj6yN|g1PSEQvF2=
LB1047-RCC NEfDVYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDMUnZpUUN3ME2yMlI1OzF5IN88US=>
MN-60 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13v[mlEPTB;Mj6yPVkzOyEQvF2=
OAW-28 NVzUflZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jxWmlEPTB;Mj6yPVk2OSEQvF2=
NCI-H2228 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjOc5FIUUN3ME2yMlMyPTV{IN88US=>
ABC-1 NEDEZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjPSmhKSzVyPUKuN|MzPTNizszN
LS-513 NX3WRlQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPsNmZKSzVyPUKuN|M1QDRizszN
KS-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7xdVJ2UUN3ME2yMlM5OTlzIN88US=>
NB69 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XFemlEPTB;Mj6zPFk5OyEQvF2=
VM-CUB-1 Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJwM{mwPFMh|ryP
D-423MG M4XIZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PaemlEPTB;Mj60NVA1PCEQvF2=
EW-18 NXvVbY4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVf5UJg{UUN3ME2yMlQyQTN7IN88US=>
YH-13 NG\qdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJwNE[xOVMh|ryP
T-24 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3i3RmlEPTB;Mj60O|g5OSEQvF2=
ES8 MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;FRmdRUUN3ME2yMlQ6Ojh5IN88US=>
ES3 NVPudVE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJwNEm3OVkh|ryP
RXF393 NYDsbXpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3mxSWlEPTB;Mj62NFQ5PyEQvF2=
RPMI-8226 M{PMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJwNkK5OVMh|ryP
AGS M3TzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTUTVJPUUN3ME2yMlczOTN5IN88US=>
HCC1395 NVfEZVlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLvcFYyUUN3ME2yMlc2OTh5IN88US=>
MV-4-11 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[xeXRrUUN3ME2yMlc2OjZ4IN88US=>
A204 NF\qVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TjUmlEPTB;Mj64N|g4OiEQvF2=
MCF7 M1fvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTFNpBbUUN3ME2yMlg3OTF5IN88US=>
SNU-423 Ml74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37nPGlEPTB;Mj64PVI1OiEQvF2=
NCI-H1048 M3eyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfyXVIzUUN3ME2yMlk3QDZ3IN88US=>
GR-ST Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3PTWM2OD1|LkC0OlEyKM7:TR?=
EoL-1- MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nZPGlEPTB;Mz6wO|A2QCEQvF2=
HuH-7 NGHPZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TuSWlEPTB;Mz6wPVQ3PCEQvF2=
OS-RC-2 NXvTPGJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTNwMUGxPUDPxE1?
EW-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTNwMUm1Nlkh|ryP
NCI-H747 NX\rXZp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\UTWM2OD1|LkKwOlk1KM7:TR?=
EW-16 Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3XTWM2OD1|LkKxPFc6KM7:TR?=
DOK NWTtUlNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXeyV3Q{UUN3ME2zMlIzQDV7IN88US=>
HCC2157 NXjNdYlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDHXVdKSzVyPUOuN|gyPzlizszN
OVCAR-3 Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkCwTWM2OD1|LkSwO|g3KM7:TR?=
NCI-H1623 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTNwNEGyNlQh|ryP
H4 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu2fpFqUUN3ME2zMlQ2PjJ4IN88US=>
SW1710 MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\PNoRKSzVyPUOuOFY3PzhizszN
RT-112 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTNwNUKzPFgh|ryP
DMS-114 M4r4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjwfXNKSzVyPUOuOlIzPzhizszN
AN3-CA MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoS0TWM2OD1|Lk[yOFU3KM7:TR?=
KNS-62 NH\T[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z1VmlEPTB;Mz62N|M{QCEQvF2=
SJRH30 MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXh[XAzUUN3ME2zMlY6OTJ{IN88US=>
G-402 NHP4d3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETxZpZKSzVyPUOuO|A4OTFizszN
MHH-PREB-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfZTWM2OD1|LkeyNFM5KM7:TR?=
P30-OHK MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DCR2lEPTB;Mz64NFk4PiEQvF2=
RVH-421 MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi4d2JKSzVyPUOuPFE4QDhizszN
LU-134-A M{jtbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTNwOEi0Nlgh|ryP
ECC10 NGLPXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DHV2lEPTB;Mz65N|YzOiEQvF2=
TGW NYP5TG1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nrdGlEPTB;ND6wNlMxPSEQvF2=
MLMA MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkSxTWM2OD12LkCyPVY3KM7:TR?=
SCC-25 NGnmSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknkTWM2OD12LkC2OVY3KM7:TR?=
TYK-nu M2LsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;oTWM2OD12LkC5OVM1KM7:TR?=
LAMA-84 NYPKRZZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfpVZBKSzVyPUSuNVQyQTFizszN
Calu-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjVTI9KSzVyPUSuNlQ1OTZizszN
NCI-H460 NXTPcm5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTRwMk[0OFMh|ryP
EGI-1 M3LJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD1blNKSzVyPUSuN|c4PzhizszN
NCI-H292 NFn6c2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3iyTmlEPTB;ND6zPFE1PiEQvF2=
HCE-T NGnuWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTRwNEG1O|kh|ryP
EW-11 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn31TWM2OD12LkSxPFM5KM7:TR?=
ATN-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LubWlEPTB;ND60OFMxPCEQvF2=
NB5 NVL4eYhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTRwNUO2PVch|ryP
KLE M4XWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nud2lEPTB;ND63NFE6QCEQvF2=
CAL-39 NVvlZ3hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17hO2lEPTB;ND63NlE1PiEQvF2=
TI-73 M4ixXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTRwOEC2NFkh|ryP
HO-1-N-1 NVjq[YNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEiyVmpKSzVyPUSuPVQzKM7:TR?=
786-0 M2L6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLHfYVYUUN3ME20Mlk1Pjd|IN88US=>
SK-N-DZ MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTRwOU[xOFIh|ryP
NCI-H446 NH3Y[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnkZ|ZKSzVyPUWuNlAxODlizszN
ETK-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTVwMkGxOlUh|ryP
BT-20 NYCybFlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XWeGlEPTB;NT6yNVM2OyEQvF2=
MEL-HO NEPpTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnkTWM2OD13LkO3N|M3KM7:TR?=
CAL-27 NHfJ[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnlTpBSUUN3ME21MlQ3OzN7IN88US=>
SW872 NVPyZph2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTVwNUm0Nlgh|ryP
RPMI-2650 NH3pUHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTVwNk[xPVkh|ryP
PFSK-1 NWjhW5VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Txb2lEPTB;NT63Nlc{OiEQvF2=
SF295 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTVwOEC2N|Mh|ryP
Becker NILaVHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUexTItyUUN3ME21Mlg3PDd{IN88US=>
Saos-2 MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTVwOE[1N{DPxE1?
SK-OV-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj4[|lVUUN3ME21Mlk6QDF4IN88US=>
VMRC-RCZ MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fxZWlEPTB;Nj6wPFc4OyEQvF2=
EW-22 NGfiNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfxXXh1UUN3ME22MlE6PjR7IN88US=>
BT-474 M3z1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\DPJo5UUN3ME22MlI{OyEQvF2=
BFTC-909 Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj1TWM2OD14LkOwN|Q2KM7:TR?=
NB12 M3TtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PTWGlEPTB;Nj6zPVA4OSEQvF2=
D-263MG NHnIWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fDN2lEPTB;Nj60OVE3QSEQvF2=
SNB75 MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M32ySmlEPTB;Nj62NFE1OyEQvF2=
A704 M4HOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLwSHRHUUN3ME22MlY{ODZizszN
NCI-H1693 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PZ[GlEPTB;Nj62N|YxPCEQvF2=
LN-405 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nTNWlEPTB;Nj63PVY4OiEQvF2=
CHL-1 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzaXVNKSzVyPU[uPFAxPzlizszN
A498 M{jYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvhXZRKSzVyPU[uPFE6PjFizszN
TE-12 M3rRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTZwOEO4NVch|ryP
TE-6 M2LUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfIflFKSzVyPU[uPVMxOzhizszN
AU565 NYfwO2hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq3dIJOUUN3ME22Mlk3QTV5IN88US=>
RD NY\DPY5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3rRWhrUUN3ME22Mlk5Ojh2IN88US=>
SW1463 NVjLN4VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTxTWM2OD15LkGxNVY5KM7:TR?=
LU-99A M3zBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfsW3ZKSzVyPUeuNVQ{OjJizszN
NCI-H28 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3W[ZlKSzVyPUeuNlkzPCEQvF2=
MC-IXC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M174V2lEPTB;Nz60PFU4PiEQvF2=
GP5d MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHrdJFMUUN3ME23MlQ5PzZ2IN88US=>
GB-1 NFKxXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f0SmlEPTB;Nz61OFgxPCEQvF2=
CAL-33 MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDLeHVKSzVyPUeuOlYzOzNizszN
MSTO-211H MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH1TWM2OD15Lk[3N|M3KM7:TR?=
TE-5 NWLMV2FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHxclVHUUN3ME23Mlc6OzN2IN88US=>
D-566MG NHzGOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRThwMES0Nlkh|ryP
JVM-3 MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPKeJE4UUN3ME24MlE2OjZ6IN88US=>
T98G NFiwV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrGTWM2OD16LkG4NFY4KM7:TR?=
HCC1954 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nrdGlEPTB;OD60OVExPCEQvF2=
SF126 MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRThwNEW5N|Yh|ryP
LB996-RCC M2XUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHWNXhKSzVyPUiuOVMzPTdizszN
SKG-IIIa Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPKTWM2OD16Lk[zNFY6KM7:TR?=
NCI-SNU-1 NGLoOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXPPJBkUUN3ME24MlY1PjR|IN88US=>
LB771-HNC NVTQOmVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRThwNkS2PVYh|ryP
SCC-4 NWi1bGROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfhXoVkUUN3ME24MlY5OjF7IN88US=>
CAMA-1 M362dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe0TnRKSzVyPUiuO|cyPDZizszN
D-502MG NX\reXdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DndGlEPTB;OD63PFYzQSEQvF2=
ESS-1 NEPjc|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRThwOEi3NFQh|ryP
HEC-1 M{jkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfqcY9KSzVyPUiuPFk5PjZizszN
NB10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTlwMEKyNlQh|ryP
8505C MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTlwMESyN|Ih|ryP
EFO-27 MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTlwMU[0NVIh|ryP
HN M3HK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fxW2lEPTB;OT6xOlYzQCEQvF2=
DSH1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjyRZZKSzVyPUmuNlA5PyEQvF2=
NBsusSR NEX4eYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\NO4xKSzVyPUmuNlc1ODJizszN
LS-123 M2fxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPITWM2OD17LkOxO|YyKM7:TR?=
SHP-77 MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXHTWM2OD17LkO5PVM2KM7:TR?=
ACN M4\WTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTlwNUOyO|ch|ryP
U251 NHSzWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrFfI5iUUN3ME25MlY2PTR2IN88US=>
A431 M{jIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fFe2lEPTB;OT64NFI{QCEQvF2=
5637 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTlwOES5PFQh|ryP
MDA-MB-157 NWW5VHFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;F[|VnUUN3ME25MlkzQDd6IN88US=>
A101D NVHncGJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\kPZhKSzVyPUmuPVk6PzRizszN
YKG-1 NF\oTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrxOplKSzVyPUGwMlIxODZizszN
LAN-6 NHPMd4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHW[ldKSzVyPUGwMlIyPjRizszN
OVCAR-5 M4nFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC4NodEUUN3ME2xNE4zPDN|IN88US=>
A549 NUfFeodTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDTTWM2OD1zMD6zPVc{KM7:TR?=
no-11 NGO5O2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fNRmlEPTB;MUCuOFM2OyEQvF2=
SF539 M{DKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFyLkmwOFEh|ryP
A388 M4WwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTKTWM2OD1zMT6zPFk4KM7:TR?=
DEL NGXqXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XxSGlEPTB;MUGuOFI1KM7:TR?=
SW954 NXf2Nm9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnVTWM2OD1zMT60OlY5KM7:TR?=
TK10 M1W2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFzLkWyO|Eh|ryP
SW756 M4L3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFzLkWyPVQh|ryP
PC-3 MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrvfWVKSzVyPUGxMlU4PjRizszN
ONS-76 M3voSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHj0dpdKSzVyPUGxMlY{PiEQvF2=
A427 NFHqboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnRNFVKSzVyPUGxMlcxQTNizszN
MEG-01 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L1eWlEPTB;MUGuO|UxQSEQvF2=
BB30-HNC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jxSGlEPTB;MUGuO|k5OiEQvF2=
NCI-H1299 MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3niRWlEPTB;MUGuPFA6OyEQvF2=
GCT M4Dx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\PdHNKSzVyPUGxMlgzOjhizszN
D-247MG NY\0WoV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD5TWM2OD1zMT65OlY{KM7:TR?=
CFPAC-1 M{CxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTFzLkm3PFIh|ryP
EKVX NFTGRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVmz[JdDUUN3ME2xNk4xOzF|IN88US=>
CAL-51 NES2cnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHQbWVKSzVyPUGyMlA4OTZizszN
BB49-HNC NF;2SI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPvTWM2OD1zMj6xNVc4KM7:TR?=
RPMI-7951 NVrvO5lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTBTWM2OD1zMj6xPFU1KM7:TR?=
RH-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\ITWM2OD1zMj6yNVg1KM7:TR?=
BCPAP Mmm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ns[GlEPTB;MUKuOFc1QSEQvF2=
GCIY NFi3NIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvZTWM2OD1zMj61NlA6KM7:TR?=
KNS-81-FD M3rBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm4O5E{UUN3ME2xNk42QDZ7IN88US=>
KYSE-140 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrONllKSzVyPUGyMlg2QTVizszN
Ca-Ski MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPQTWM2OD1zMj65NFQyKM7:TR?=
TGBC1TKB M{ixZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrETFdKSzVyPUGyMlkyOTVizszN
HCC1187 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnoeohpUUN3ME2xN{4yQTF{IN88US=>
SJSA-1 NYP3[WU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLNdlNKSzVyPUGzMlI{OjdizszN
CTV-1 MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnB[ngzUUN3ME2xN{4{PDVizszN
WM-115 M4\Pe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TaNWlEPTB;MUOuOlQ5OyEQvF2=
CHP-212 M3;URmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq5NoVNUUN3ME2xN{46PzN7IN88US=>
SCC-15 NEDlWoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrpNVB3UUN3ME2xN{46Pzd3IN88US=>
BPH-1 Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPZ[FNKSzVyPUG0MlE3PjRizszN
SW780 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\qVY57UUN3ME2xOE42ODJ3IN88US=>
NCI-H2291 MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXkVW9KSzVyPUG0MlU5PzhizszN
JEG-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF2Lk[zNlYh|ryP
CAL-120 MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLtfnpRUUN3ME2xOE44ODJ5IN88US=>
NCI-H23 Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL0dIlKSzVyPUG0Mlc6QTdizszN
MS-1 NVXXXmZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHGSoRKSzVyPUG0Mlk3OTFizszN
PC-14 NFHoVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXZNoNKSzVyPUG0Mlk3PTRizszN
D-283MED M1Ly[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPNTWM2OD1zNT6wNVEyKM7:TR?=
OE19 M1ezNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDIfGR3UUN3ME2xOU4yPTRzIN88US=>
CAS-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPGPY4zUUN3ME2xOU41OTh2IN88US=>
NCI-H727 NGXRcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlK3TWM2OD1zNT60NlIyKM7:TR?=
SiHa M1XrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILzNnpKSzVyPUG1Mlc2QTRizszN
BFTC-905 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TMfmlEPTB;MUWuO|Y6PCEQvF2=
MDA-MB-453 M1LiWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX0TWM2OD1zNj6xOlQzKM7:TR?=
HuP-T3 NUXzTY1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF4Lk[zO|Mh|ryP
SK-LU-1 Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi1TWM2OD1zNj62PVU3KM7:TR?=
Detroit562 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKxOVZKSzVyPUG2Mlc{OThizszN
HCC1569 M{nkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF4LkizN|ch|ryP
SK-MES-1 NELqXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF4Lki0NVkh|ryP
BB65-RCC M4DBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;rTmlEPTB;MUeuNFQ4QSEQvF2=
LOXIMVI MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LoXmlEPTB;MUeuNFcxPyEQvF2=
SW1783 MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\iO4hVUUN3ME2xO{4yOjhizszN
NH-12 NV3INplOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jtPGlEPTB;MUeuN|MxOyEQvF2=
UACC-257 NWjZO5M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\FT29qUUN3ME2xO{42PTF{IN88US=>
KOSC-2 Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTReII{UUN3ME2xO{43PzV5IN88US=>
KG-1 M4LWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfNbGxKSzVyPUG3MlY6OzdizszN
M059J MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3xdWJKSzVyPUG3MlcxOyEQvF2=
MHH-NB-11 NFHDdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\6d2lKSzVyPUG3Mlk3PzNizszN
EW-1 MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnBe2RtUUN3ME2xPE4yOzh{IN88US=>
CAL-85-1 MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjHTWM2OD1zOD6yN|U4KM7:TR?=
639-V M33TTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPaPJI3UUN3ME2xPE4{OzV2IN88US=>
C32 NXzofZJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfvTWM2OD1zOD60O|I4KM7:TR?=
KM-H2 MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jKNmlEPTB;MUiuOVI{OiEQvF2=
A253 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF6LkeyPFYh|ryP
NCI-N87 MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ryeWlEPTB;MUiuPVAxQCEQvF2=
8-MG-BA MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{CxTGlEPTB;MUmuNFY1PiEQvF2=
GI-ME-N M{jJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rCdGlEPTB;MUmuNVU1PiEQvF2=
8305C NYrTUYNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\3[4RZUUN3ME2xPU4zOjh4IN88US=>
TE-8 M3LwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF7LkOwNlQh|ryP
KYSE-270 NELOe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLwZmVKSzVyPUKwMlAzOTdizszN
HL-60 M1\uSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJyLkC5OFEh|ryP
Mo-T M3H3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfm[GRKSzVyPUKwMlE3PjVizszN
NCI-H1355 NILrfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfyfGtOUUN3ME2yNE4{Ozd2IN88US=>
HT-1080 NH20[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LBeWlEPTB;MkCuOVQ6PyEQvF2=
MIA-PaCa-2 MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj2TWM2OD1{MD62PFg{KM7:TR?=
NCI-H441 NVPJc3R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPwcHBCUUN3ME2yNE44Ozd7IN88US=>
LCLC-97TM1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jWZ2lEPTB;MkCuPFE{PCEQvF2=
HT-3 MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJzLkW2N|Eh|ryP
22RV1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJzLkW2PFUh|ryP
LK-2 NXHGRppRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJzLkW5OVMh|ryP
CW-2 MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\hWmlEPTB;MkGuOlA3QSEQvF2=
KYSE-510 MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PVZmlEPTB;MkGuOlA6PSEQvF2=
CGTH-W-1 M4P6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPkTWM2OD1{MT63NVY3KM7:TR?=
NCI-H661 NInBPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnH[Gg1UUN3ME2yNk4xOzRizszN
KU-19-19 NV3h[W9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHi3dYpKSzVyPUKyMlE3QTdizszN
NCI-H2122 M1uzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzlWGx2UUN3ME2yNk4zPDN{IN88US=>
NCI-H526 NYHTU|FzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\KU4g1UUN3ME2yNk4{QDl3IN88US=>
NCI-H1650 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Pt[2lEPTB;MkKuO|Y1KM7:TR?=
AM-38 M3XXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJ{Lki2PFkh|ryP
NCI-H2405 NYTTWmp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrDZ2lYUUN3ME2yN{4zPTN|IN88US=>
M14 Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn3WYtKSzVyPUKzMlQxQDhizszN
ES4 NHjURo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJ|LkSyN|Ih|ryP
DJM-1 NG[3ZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\wUpdWUUN3ME2yN{42OjN2IN88US=>
S-117 NGK3O4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPZTWM2OD1{Mz63OlUyKM7:TR?=
MZ2-MEL MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS2NlNMUUN3ME2yN{44PzV7IN88US=>
SK-MEL-2 NFGz[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;RTWM2OD1{Mz64NVM{KM7:TR?=
HCC1806 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjpbZFKSzVyPUKzMlg4ODlizszN
NMC-G1 MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jifWlEPTB;MkSuNlIzPiEQvF2=
DK-MG NUnybFhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zLRWlEPTB;MkSuNlk1KM7:TR?=
SK-N-FI NEnqd4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\sZYlXUUN3ME2yOE4{OzB{IN88US=>
KINGS-1 NXn3[IxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXneVV5UUN3ME2yOE41QDd2IN88US=>
HCC2998 Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TE[GlEPTB;MkSuOFg5PSEQvF2=
ALL-PO MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nNZWlEPTB;MkSuOlE6KM7:TR?=
MPP-89 NW\Ke2pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJ3LkC0OVgh|ryP
NCI-H2342 M1zPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJ3LkG5OVMh|ryP
TE-1 M2TBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G4UGlEPTB;MkWuN|U3OyEQvF2=
RH-18 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvrTWM2OD1{NT61PVE5KM7:TR?=
HT-1376 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\GS4Z1UUN3ME2yOU43PDZ3IN88US=>
U-2-OS MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJ3Lk[4PFgh|ryP
BT-549 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;GdWlEPTB;MkWuPVAyOSEQvF2=
NCI-H1755 NH73WpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e5eWlEPTB;MkWuPVk1PSEQvF2=
EW-13 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW1bI45UUN3ME2yOk4xOjd2IN88US=>
NB13 Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3weWk6UUN3ME2yOk4xQTR7IN88US=>
NUGC-3 M1fNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe0bWdWUUN3ME2yOk4zOTB|IN88US=>
GMS-10 NWHaW|hkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[2cJNKSzVyPUK2MlI{PTNizszN
CHP-134 NVLmOIp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17W[GlEPTB;Mk[uN|g3PyEQvF2=
SW962 M4j2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLDVodKSzVyPUK2MlUxOjFizszN
SNU-449 NITLbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLjeY9HUUN3ME2yO{4xQDB|IN88US=>
HuP-T4 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PJeGlEPTB;MkeuNFg4QSEQvF2=
SW948 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJ5LkGzOFQh|ryP
NCI-H226 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXMcWpKUUN3ME2yO{41PTd6IN88US=>
SK-PN-DW M4HIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJ5Lk[wNVIh|ryP
GI-1 M3m1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDzZpNnUUN3ME2yO{44OjFizszN
CAL-12T NYTkXplHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[4dGEzUUN3ME2yPE4yOTF{IN88US=>
YAPC MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJ6LkK1OlQh|ryP
SNU-C2B NH;Y[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HNSGlEPTB;MkiuNlk3PCEQvF2=
RCC10RGB NV;iOW5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHzNFIxUUN3ME2yPE42PDF5IN88US=>
ES7 M3nC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS0b4VSUUN3ME2yPU4yPDZ3IN88US=>
PANC-03-27 M4fTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTuRWlYUUN3ME2yPU41PDRizszN
ES6 NUDNbZBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vRbWlEPTB;MkmuPFE2PyEQvF2=
HT-1197 NULkb2JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTNyLkC1PVgh|ryP
ZR-75-30 NWPKTIpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnUTWM2OD1|MD6yN|g{KM7:TR?=
DB M360ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nEcmlEPTB;M{CuOFk1OiEQvF2=
OCI-AML2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLmNXNKSzVyPUOxMlA3QSEQvF2=
NCI-H2170 MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXEZWtKSzVyPUOxMlg2OTZizszN
IST-MES1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTN{LkK4PVch|ryP
769-P MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTN{LkO2OFEh|ryP
COR-L23 NEDZR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;VTWM2OD1|Mj65NFc{KM7:TR?=
SW626 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTN|LkG3O|Yh|ryP
LU-139 Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTN|Lk[2NFUh|ryP
HT-144 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfISW1KSzVyPUOzMlg3OyEQvF2=
CaR-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLkWphiUUN3ME2zN{46QDJ{IN88US=>
OE33 NUTvXHlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojXTWM2OD1|ND6yPFU2KM7:TR?=
COLO-800 NVfDS|lCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\NPZV5UUN3ME2zOE4{PjR5IN88US=>
NB14 NFvt[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nZUWlEPTB;M{SuOFY5PCEQvF2=
KURAMOCHI M4jKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M331T2lEPTB;M{[uNVE6QCEQvF2=
SW48 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrLTWM2OD1|Nj6yOFc1KM7:TR?=
Daoy NHi3WI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzaTWM2OD1|Nj62OVM5KM7:TR?=
TGBC24TKB Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnqyTWM2OD1|Nj62O{DPxE1?
DU-4475 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLGXIxKSzVyPUO2MlkxOzNizszN
SW1417 M1rQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTN6LkC1OVIh|ryP
EFO-21 MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTN6LkmzOFkh|ryP
MG-63 M3f2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDEW5hKSzVyPUO5MlM1OjRizszN
LC-2-ad MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTN7LkW1NVIh|ryP
NOMO-1 NInTTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPOTWM2OD1|OT64Nlc1KM7:TR?=
COLO-741 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTQcppKSzVyPUSwMlE{ODRizszN
BxPC-3 NHn0c3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LuPGlEPTB;NECuOVY5PiEQvF2=
HSC-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIWxOY1KSzVyPUSwMlkyOTNizszN
UMC-11 M1Lzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLNTWM2OD12MT6yOlMh|ryP
HCC1937 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTR{Lke4OFMh|ryP
Calu-6 M125UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\iSIE2UUN3ME20N{4zOzh{IN88US=>
NCI-H1573 M2T5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D4cmlEPTB;NEOuN|Q4PyEQvF2=
SK-N-AS MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf0PW1zUUN3ME20N{43ODF7IN88US=>
PSN1 MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHnboREUUN3ME20OU4zPTR6IN88US=>
TE-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTR3LkS4OFIh|ryP
NCI-H1155 NVLYeI56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULPT49SUUN3ME20OU45QTZ5IN88US=>
KM12 NXjWeFVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLjTWM2OD12NT65NFc3KM7:TR?=
RO82-W-1 NXTMd2dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLy[oI5UUN3ME20Ok46QDJ{IN88US=>
SW1573 MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvCV|VoUUN3ME20O{4{PzN4IN88US=>
CAKI-1 MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETYS3RKSzVyPUS4MlI5PDVizszN
U-118-MG NHzrbFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTR6LkO3NFIh|ryP
KYSE-520 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWftWHlVUUN3ME20PE41ODF4IN88US=>
HT55 NYLPSWVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTR7LkG0O|Qh|ryP
ChaGo-K-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkK5TWM2OD12OT60O|k{KM7:TR?=
IA-LM MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTV2Lk[zNlIh|ryP
UACC-62 M{nFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTV3LkGwOFYh|ryP
MKN7 NGWwbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInMVIFKSzVyPUW2MlAzQDVizszN
HPAF-II NWjVNpJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe5TWM2OD13Nj60NFc{KM7:TR?=
NTERA-S-cl-D1 NYDVW4RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rMVmlEPTB;NUeuO|c5KM7:TR?=
FTC-133 MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1faNmlEPTB;NUiuNFk3QSEQvF2=
MHH-ES-1 NXHzWFh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq5WmhKSzVyPUW4MlQ5OTRizszN
JVM-2 NWX3ZlNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\r[XlxUUN3ME21PE46PTB4IN88US=>
TCCSUP NEf1O29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjBTWM2OD13OT61Nlc6KM7:TR?=
COLO-824 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi5TWM2OD14MD6wO|E6KM7:TR?=
647-V M2m3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTZyLkGzOFch|ryP
HD-MY-Z M3nFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX0TWM2OD14MD61Nlk1KM7:TR?=
LS-411N MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2GwVmlEPTB;NkGuN|kxOyEQvF2=
NCI-H596 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\vTWM2OD14Mj63OFk3KM7:TR?=
C-33-A NGm0dIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTZ2LkC5OVch|ryP
BHY MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTZ2LkGyOFUh|ryP
KGN NWH3UopTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jNPGlEPTB;NkSuOVUyPCEQvF2=
NCI-H1092 NGrGUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTZ3LkCwPVUh|ryP
MZ1-PC NYGwOZBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\TS4x2UUN3ME22OU42PjR7IN88US=>
LB831-BLC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPGTWM2OD14NT64OFgyKM7:TR?=
SW620 Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXPTWM2OD14Nj6yNFM6KM7:TR?=
HuO-3N1 NFjjUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DaVmlEPTB;NkiuN|I{QCEQvF2=
SK-HEP-1 NFjMfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPlV3N5UUN3ME22PU46PDh4IN88US=>
LCLC-103H NWDzN2lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTESoZKSzVyPUewMlY4ODVizszN
KYSE-70 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTdyLke4N|Uh|ryP
Mewo M2rDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml35TWM2OD15MT61NFUh|ryP
COLO-668 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTdzLki0OVEh|ryP
NCI-H522 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPuTWM2OD15Mj6zOFE{KM7:TR?=
NCI-H1437 M{HufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWmyOHlOUUN3ME23OE41ODR6IN88US=>
U-266 MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTd3LkS1NVYh|ryP
MC116 NHS3bI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTd3LkW3NFgh|ryP
PANC-10-05 NFrmd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M136[WlEPTB;N{euOFI1OyEQvF2=
KYSE-180 MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\zemlEPTB;N{euOVQ2PCEQvF2=
JAR MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjzRlJtUUN3ME23PU4xPTR4IN88US=>
CAL-62 MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRThyLkC5OUDPxE1?
A3-KAW MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojaTWM2OD16MD6yNVU1KM7:TR?=
PANC-08-13 M1L3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRThzLkG3Olgh|ryP
HSC-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTKUXhUUUN3ME24N{4{ODdzIN88US=>
HTC-C3 NXyzXFVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPvXolKSzVyPUizMlQ4ODJizszN
KY821 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTZTWM2OD16ND6wPFkzKM7:TR?=
DoTc2-4510 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nJ[2lEPTB;OESuNlE5PSEQvF2=
NCI-H1581 NWHWXYY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELGfnpKSzVyPUi1MlQ3PDFizszN
KARPAS-299 MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTh4LkG5O|ch|ryP
IST-MEL1 M3rl[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzOW49KSzVyPUi2Mlg5PzJizszN
KP-N-YS MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfsPZV1UUN3ME24PU46ODJ6IN88US=>
KYSE-410 MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTlzLkSwOFIh|ryP
TE-10 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;2TWM2OD17MT61OlEyKM7:TR?=
SK-MEL-1 NEfuZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\vTWM2OD17Mj65NVA3KM7:TR?=
COLO-792 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPQTWM2OD17NT6yOVY1KM7:TR?=
SCH NFixUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj5U|kyUUN3ME25Ok4{QDd5IN88US=>
NCI-H1792 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7YTYZKSzVyPUm2Mlg6QTJizszN
NCI-H2029 NGLPNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XCcmlEPTB;OU[uPVU3PiEQvF2=
SW684 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fLNGlEPTB;OUiuOlY2PCEQvF2=
NCI-H209 M3nGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFyMD6xNlEh|ryP
HLE M{nYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml2zTWM2OD1zMEWuNlgzKM7:TR?=
GOTO NXr1O4pFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFyNz63O|ch|ryP
NCI-H1793 NF24TmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHnZnM3UUN3ME2xNFkvOjhizszN
D-392MG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3NfYRKSzVyPUGxO{4{QThizszN
SW1990 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELQUpBKSzVyPUGyNE46PTFizszN
ML-2 M1;lfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTF{MT62O|Yh|ryP
NCI-H2452 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;1OVB2UUN3ME2xNlIvOjFizszN
SK-MEL-30 NHHCOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF{Mz6yOFQh|ryP
SN12C NUnVeZFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;keYFNUUN3ME2xNlQvOTd4IN88US=>
NCI-H1770 MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\MS2lEPTB;MUK1MlUyPCEQvF2=
SF268 M1[xUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfJTWM2OD1zMk[uNVU5KM7:TR?=
BALL-1 NFPwOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33tcWlEPTB;MUK2MlI{KM7:TR?=
COLO-679 M2Xac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH0cHZMUUN3ME2xNlYvPzV|IN88US=>
A2780 M4T6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\xXop6UUN3ME2xNlgvQTh6IN88US=>
NCI-H1651 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDoO4d6UUN3ME2xN|EvOjR|IN88US=>
NCI-H2087 M1qxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HTSWlEPTB;MUOxMlQ5OyEQvF2=
U-87-MG NGeyN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XscWlEPTB;MUOzMlYxPCEQvF2=
LB2518-MEL NYq0OXIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEGyXWRKSzVyPUGzOU46QTNizszN
HCT-116 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;5SmlEPTB;MUO3MlIyPyEQvF2=
Ca9-22 M4Sx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfHeYZ1UUN3ME2xN|kvQDN|IN88US=>
COR-L88 NHPS[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3DTWM2OD1zNEKuNVQh|ryP
CP50-MEL-B NWfKUWx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHiTWM2OD1zNESuOVAyKM7:TR?=
OVCAR-8 NYW1XHNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHGU2ZKSzVyPUG0OU43OzZizszN
SK-MEL-3 M4\wOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELKV4hKSzVyPUG0O{45PzhizszN
GT3TKB NFG4[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjoSpdKSzVyPUG0PU46OjhizszN
KYSE-450 M4G1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF3MT61N|kh|ryP
CAPAN-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPuZ3FKSzVyPUG1N{4xPjRizszN
BEN MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK1clNKSzVyPUG1N{46OjhizszN
NCI-H1304 M{fSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DD[mlEPTB;MUW0MlY6PCEQvF2=
KU812 MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXDTWM2OD1zNUiuOlc1KM7:TR?=
Capan-2 NXHxdmhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHHTWM2OD1zNkCuOVU{KM7:TR?=
A673 NIq3TZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmiyTWM2OD1zNkGuO|A2KM7:TR?=
SAS MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLrdnFKSzVyPUG2Nk43PzhizszN
NY MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M123eWlEPTB;MU[1MlMyPCEQvF2=
HCE-4 NYTqcm9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF4Nj64OFUh|ryP
MDA-MB-231 NV3nT5J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS4[ZNCUUN3ME2xO|cvPTB|IN88US=>
no-10 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T4VGlEPTB;MUe4MlE{PCEQvF2=
MZ7-mel NGTtNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TX[mlEPTB;MUe4MlQ3PyEQvF2=
NCI-H82 MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;jTWM2OD1zOECuNVY2KM7:TR?=
CAL-72 M1;6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\5TWM2OD1zOEWuNFU1KM7:TR?=
NCI-SNU-5 NETLUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[wNWJKSzVyPUG4Ok45PCEQvF2=
OVCAR-4 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFqyZ|JKSzVyPUG4PE4{OzNizszN
SCC-9 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j6WWlEPTB;MUmxJO69VQ>?
KYSE-150 MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHBUXU4UUN3ME2xPVEvQDh6IN88US=>
HT-29 NWKyU|hKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJyMT6yNVIh|ryP
COLO-678 NHL2cIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzwcGpKSzVyPUKwNU41PSEQvF2=
NCI-H650 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HLXWlEPTB;MkCyMlExOyEQvF2=
HuCCT1 MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XJb2lEPTB;MkC0MlIxQCEQvF2=
SW1116 NXTtZmVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6zVVc5UUN3ME2yNFcvODd5IN88US=>
DBTRG-05MG M3PSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3WdIFKSzVyPUKwO{46ODlizszN
SW982 NHflS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[1cVBiUUN3ME2yNFcvQTR6IN88US=>
RCM-1 M1[xTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHZPWhtUUN3ME2yNVQvPzZ{IN88US=>
COLO-320-HSR NV7FU5U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDKeHpZUUN3ME2yNVYvOTJ3IN88US=>
KNS-42 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z6bGlEPTB;MkG2MlU4PCEQvF2=
C2BBe1 NH3CV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS2TWM2OD1{M{GuPVA2KM7:TR?=
CCRF-CEM M2Pw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJ2Mz63PVUh|ryP
SH-4 MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7XZ3V7UUN3ME2yOFYvODlizszN
LS-1034 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXzTWM2OD1{NE[uNlY3KM7:TR?=
NCI-H2347 M2faRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M16yS2lEPTB;MkS3MlcyOyEQvF2=
RPMI-8866 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS3TWM2OD1{NEmuNlch|ryP
GAK M335cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\NVI9KSzVyPUK1N{4xODJizszN
NB6 M2LGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rScWlEPTB;MkewMlEh|ryP
COLO-680N M2PkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJ5Mj61Nlch|ryP
RERF-LC-MS NYj6W2VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPsSHlKSzVyPUK3Ok4xODdizszN
TGBC11TKB MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHweVR5UUN3ME2yO|gvOTd6IN88US=>
C8166 NXnS[pByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTMTWM2OD1{N{iuOVA3KM7:TR?=
HDLM-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrNSHNoUUN3ME2yPVQvPDB7IN88US=>
IGR-1 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrqNWpCUUN3ME2yPVUvPjV7IN88US=>
FADU M4X4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHu[FFKUUN3ME2yPVcvPTFizszN
L-428 MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHv[HJZUUN3ME2yPVcvPjF4IN88US=>
LU-65 NIPuVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvkXJdVUUN3ME2zNFQvOzJizszN
HEL NYjiPG9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnNTWM2OD1|MEmuPVg{KM7:TR?=
NCI-H810 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\3NIU6UUN3ME2zNVAvPTdizszN
C3A MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTNzMT64NFIh|ryP
NCI-H630 M2DGWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PRUGlEPTB;M{OyMlI6PCEQvF2=
KP-N-YN MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzITWM2OD1|NEGuNVI{KM7:TR?=
MOLT-13 M{[1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX61fHlIUUN3ME2zOFIvOzJ4IN88US=>
NCI-H1993 NITwcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjscFVKSzVyPUO0Nk4{PjVizszN
BE-13 NGHqNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7TTWM2OD1|NESuNVY4KM7:TR?=
IST-SL1 Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf0dlk4UUN3ME2zOFcvPDBzIN88US=>
TE-9 NG[3cVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHNXZFKSzVyPUO2N{42QDlizszN
LU-135 NGPFN|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHVdYkzUUN3ME2zOlcvODN3IN88US=>
T84 NWHRcHJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzFTWM2OD1|N{SuO|EzKM7:TR?=
K-562 MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTN6Mz6zOkDPxE1?
SBC-5 MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7EPG5KSzVyPUO4Ok46QDVizszN
NB17 NX3RTo5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTN7Mj61PVYh|ryP
NCI-H2052 NETCOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTsTWM2OD1|OUiuOFczKM7:TR?=
HCC38 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPRdXZRUUN3ME20NFEvPTl|IN88US=>
NCI-H69 MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjmc3hLUUN3ME20OFEvODh|IN88US=>

... Click to View More Cell Line Experimental Data

In vivo試験 MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]
臨床試験 MK-2206 is currently under Phase II clinical trial for treatment of ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
特集 The first allosteric small molecule inhibitor of Akt to enter clinical development.

プロトコル (参考用のみ)

キナーゼアッセイ: [4]

Akt kinases assay Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.

細胞アッセイ: [2]

細胞株 A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
濃度 0, 0.3, 1 and 3 μM
反応時間 72 or 96 hours
実験の流れ MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.

動物実験: [2]

動物モデル SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
製剤 Formulated in 30% Captisol
投薬量 120 mg/kg
投与方法 Orally administered

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download MK-2206 2HCl SDF
分子量 480.39
化学式

C25H21N5O.2HCl

CAS No. 1032350-13-2
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 14 mg/mL (29.14 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 15% Captisol 17 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one

カスタマーフィードバック (19)


Click to enlarge
Rating
Source Cancer Cell, 2013, 24, 766-76. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines T-ALL cells
Concentrations 10 uM
Incubation Time 5 h
Results western blot analysis with the AKT phosphorylationmotif antibody showed decreased AKT phosphorylated NR3C1in NR3C1 immunoprecipitates from CCRF-CEM T-ALL cellsupon AKT inhibition with MK2206

Click to enlarge
Rating
Source Cancer Cell, 2013, 24, 766-76. MK-2206 2HCl purchased from Selleck
Method flow cytometry
Cell Lines immunodeficient NOG mice
Concentrations 10 mg kg-1
Incubation Time 3 days
Results AKT1 inhibition of CCRF-CEM lymphoblasts with MK2206 effectivelyrestored glucocorticoid-induced apoptosis and reversed glucocorticoid resistance in vitro.

Click to enlarge
Rating
Source Cancer Cell, 2013, 24, 766-76. MK-2206 2HCl purchased from Selleck
Method analysis of luciferase activity
Cell Lines immunodeficient NOG mice
Concentrations 10 mg kg-1
Incubation Time 3 days
Results In this experiment, animalstreated with dexamethasone or MK2206 showed progressivetumor growth similar to that observed in vehicle-treated controls,while mice treated with MK2206 plus dexamethasone had significant antitumor responses.

Click to enlarge
Rating
Source Cancer Discov, 2012, 2, 934-47. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines PC9GR4/WZR10 cells
Concentrations 1 uM
Incubation Time 72 h
Results The addition of a dual PI3K and MTOR inhibitor, PI103, or the AKT inhibitor MK-2206, did reduce the expression of pAKT neither in GR4 cells nor WZR10 cells.

Click to enlarge
Rating
Source J Exp Med, 2014, 211(9), 1741-58. MK-2206 2HCl purchased from Selleck
Method 3D migration model
Cell Lines WT or Rap1b-/- neutrophil
Concentrations 2 uM
Incubation Time
Results MK-2206 treatment completely reversed elevated TEM across mouse endothelial cells of Rap1b-/- neutrophils to WT levels (A). It reduced ECM degradation of Rap1b -/- neutrophils, and inhibited their multiple protrusions (B and C). Furthermore, almost all Rap1b -/- cells treated with MK-2206 were found at the endothelial cell junctions (D).

Click to enlarge
Rating
Source Nat Commun, 2015, 6:6943. MK-2206 2HCl purchased from Selleck
Method Western Blot
Cell Lines HUVECs
Concentrations 1 uM
Incubation Time 8 h
Results Because YAP is also a known substrate of Akt21, we examined whether blockade of the Akt pathway affects YAP phosphorylation. Both Ly294002, an inhibitor of phosphoinositide 3-kinase (PI3K), and MK-2206, an allosteric inhibitor of Akt, suppressed cell contact-mediated YAP phosphorylation.

Click to enlarge
Rating
Source Leukemia, 2015, 29(1), 169-76. MK-2206 2HCl purchased from Selleck
Method Immunoblotting
Cell Lines CXCR4S338X-expressing BCWM.1 cells
Concentrations 0.5 uM
Incubation Time 6 h
Results As AKT and ERK, but not BTK, show continued SDF-1a-triggered activation in CXCR4S338X-expressing WM cells treated with ibrutinib, we next sought to clarify if AKT and ERK contributed to the enhanced survival of these cells. It therefore treated SDF-1acultured CXCR4S338X BCWM.1 cells with either AKT- (MK-2206 and AZD-5363) or MEK- (AS-703026, AZD-6244 and UO126) specific inhibitors with and without ibrutinib (0.5 uM) for 6 h so as to clarify the contribution of AKT and ERK to ibrutinib resistance. The inhibitory activity of MK-2206, as well as AS-703026, AZD-6244 and UO126 was confirmed by western blot analysis for pAKT (S473) and pERK (T202/Y204), respectively.

Click to enlarge
Rating
Source Cancer Res, 2013, 73, 2189-98. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines SKNAS/SJNB8/IMR32/GIMEN/SHEP2/KCNR/NGP/LAN1/LAN5/TR14/UHGNP cell lines
Concentrations 8 μM
Incubation Time 48 h
Results The 8 μM MK-2206 treatments resulted in effective pathway inhibition in all cell lines as shown by western blot for phosphoryl ated FOXO3a and PRAS40 as well as AKT serine 473 phosphorylation.

Click to enlarge
Rating
Source Oncotarget, 2011, 2, 1109-26. MK-2206 2HCl purchased from Selleck
Method Western blot/ Wst-1 assay
Cell Lines ATC/ FTC cell lines
Concentrations 500 nM
Incubation Time 1 h/72 h
Results One-hour treatment with the AKT inhibitor MK-2206 (0.5 μM) or with the MEK inhibitor U0126 (10 μM) effectively abolished AKT and ERK1/2 phosphorylation in all cell lines.

Click to enlarge
Rating
Source Sci Signal, 2011, 4, rs9. MK-2206 2HCl purchased from Selleck
Method ELISA
Cell Lines HeLa cells
Concentrations 1 μM
Incubation Time
Results Treatment of infected cells with kinase inhibitors directed at Akt (MK-2206), MEK(PD 98059), PKC(CEC), or Pim family kinases identified a dominant role for Pim family kinases in the release of IL-8 from Salmonella-infected epithelial cells.

Click to enlarge
Rating
Source FASEB J, 2013, 27, 1644-56. MK-2206 2HCl purchased from Selleck
Method Clonogenic growth assay
Cell Lines U2OS cells
Concentrations 1 μM
Incubation Time 9 d
Results Specific inhibition of PKB activity using MK-2206 or triciribine also significantly reduced cell growth, although to a lesser extent compared to PI-103, suggesting that both the PKB and mTOR pathways are important for anchorage-dependent growth.

Click to enlarge
Rating
Source Gynecol Oncol, 2011, 123, 13-8. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines ovarian cancer cell lines
Concentrations 1-6 μM
Incubation Time 1 h/72 h
Results Activation of pAKT by IGF-1 in the low-grade cell line HOC-7 was blocked by the AKT inhibitor MK-2206.

Click to enlarge
Rating
Source J Cell Biochem, 2011, 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Confocal microscopy
Cell Lines platelets
Concentrations 1μM
Incubation Time
Results Upon treatment with increasing concentrations of AEA from 0.1 to 10 mM (Fig. B–D) platelets were fully fluorescently marked as compared to control (Fig. A) and the increase in DAF 2 fluorescence intensity appears to be dose-dependent. In agreement with data shown in Figure 4, SR1(Fig. E) and MK2206 (Fig. F) abolished fluorescence intensity induced by AEA, while LY294002 (Fig. 5G) was less potent.

Click to enlarge
Rating
Source J Cell Biochem, 2011, 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines platelets
Concentrations 1 μM
Incubation Time
Results eNOSser1177 phosphorylation was greatly reduced by LY294002 and cancelled by MK2206 but it was not modified by platelet pretreatment with EGTA or BAPTA/AM.

Click to enlarge
Rating
Source J Cell Biochem, 2011, 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Nitriter+Nitrate(NOX) measurement, cGMP detection
Cell Lines platelets
Concentrations 1 μM
Incubation Time 1 min
Results As shown in Figure 4 SR1 significantly reduced both NOx and cGMP formation, while SR2 failed to affect these parameters.

Click to enlarge
Rating
Source Radiat Oncol, 2009, 4, 43. MK-2206 2HCl purchased from Selleck
Method Western blot, clonogenic survival assay
Cell Lines U87MG cells
Concentrations 1 μM
Incubation Time 1 h
Results Akt inhibitor MK-2206 showed similar effect. MK-2206 is a potent allosteric Akt inhibitor with IC50 at 8 nm, 2 mM, 65 mM for Akt1, Akt2 and Akt3 respectively. U87MG cells were preincubated with 1 μM MK-2206 for 1 hr, followed by irradiation at 0 - 9 Gy. As shown in Fig C, MK-2206 treatment abolished IR-induced Akt phosphorylation. Moreover, treatment with MK-2206 also increased the radiosensitivity of U87MGcells (Fig. D)

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-10 nM
Incubation Time 3 h
Results Breast cancer cells were serum starved for 24 h, pretreated with the indicated concentrations of MK-2206 for 3 h, and then treated with 100ng/ml EGF for 15 min.

Click to enlarge
Rating
Source Biochim Biophys Acta, 2012, 1823, 987-96. MK-2206 2HCl purchased from Selleck
Method Immunofluorescence
Cell Lines HC11 cells
Concentrations 10 µM
Incubation Time 1 h
Results whole ADRP levels, estimated by Western blot , decreased only in the presence of MK -2206 and LY294002. In most cases, ADRP decorated the surface of small lipid droplets and appeared as little patches on large cytoplasmic lipid droplets. With the exception of SP600125, which induced a strong ADRP coating of almost all cytoplasmic lipid droplets (although this inhibitor did not increase ADRP synthesis), variation in the distribution of ADRP at the surface of lipid droplet was difficult to estimate, notably because the signal was faint and uneven.

Click to enlarge
Rating
Source MK-2206 2HCl purchased from Selleck
Method Western blot analysis
Cell Lines MCF-7 cells
Concentrations 0 nM/100 nM/250 nM/1000 nM
Incubation Time 24 h
Results The effect of MK-2206 on the serine 473 phosphorylation mark of AKT 1 was uneven and did not correlate with inhibition of AKT activity, but the AKT1 mutant cells maintained higher levels of AKT1 serine 473 phosphorylation with increasing concentrations of MK-2206. Of note, MK-2206 completely inhibited AKT2 activation at 100 nM, a concentration where PIK3CA E545K mutant, but not AKT1 mutant cells were already strongly growth inhibited. MK-2206 treatment up to 1 μM did not have strong effects on other protein biomarkers such as ribosomal protein S6, ev en though growth was suppressed by approximately 80% in MCF-7 cells at this concentration.

文献中の引用 (166)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Akt 阻害剤

  • AT13148

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • SC79

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • LY2090314

    LY2090314 は GSK-3α と GSK-3βのために、強力なGSK-3阻害剤で、IC50 がそれぞれ1.5 nM と 0.9 nMです。

  • AZD5363

    AZD5363は、有力なAkt阻害剤で、Akt1、Akt2とAkt3に作用すると、 IC50がそれぞれ 3 nM、 8 nM 、 8 nMです。

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068)は、5nM、18nMと8nMのIC50でAkt1、Akt2とAkt3を目標としている非常に選択的な汎Akt阻害剤です。

  • GSK690693

    GSK690693は、Akt1、Akt2とAkt3を目標としている汎Akt阻害剤で、IC50 がそれぞれ 2 nM、13 nM、9 nMです。

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401)は、4.7 nMのIC50による新しいAkt阻害剤です。

  • A-674563

    A-674563は、Akt1 抑制影響を示しまして、Ki が 11 nMです。

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

最近チェックしたアイテム

Tags: MK-2206 2HClを買う | MK-2206 2HCl供給者 | MK-2206 2HClを購入する | MK-2206 2HCl費用 | MK-2206 2HCl生産者 | オーダーMK-2206 2HCl | MK-2206 2HCl代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
お問い合わせ